Athira Pharma Reports Reduced Losses Amid Cost Cuts
I'm PortAI, I can summarize articles.
Athira Pharma, Inc. reported its Q3 earnings, showing a reduced net loss of $6.6 million, down from $28.7 million a year prior. This improvement is due to significant cuts in operating expenses, particularly in research and development, which decreased to $2.8 million from $17.9 million. Despite these gains, the company faces challenges, including the need for additional funding. Athira's management is focused on advancing its drug pipeline, especially ATH-1105, while seeking strategic transactions to enhance its financial stability.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments